This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
As company-leaders plan for the year ahead, they should consider why a 3 rd party on-site strategic intelligence resource might be good for business. For more than 40 years, Fuld + Company has partnered with its clients to deliver strategic insights, guidance and industry analysis that support executive decision-making. Our engagements manifest in many ways, and more recently, our clients are requesting continuous, on-site decision support from us, either because they have identified a need to g
Oftentimes there are numerous agents within a class of medication. Ropinirole (Requip) and pramipexole (Mirapex) is an example of this. When comparing ropinirole and pramipexole, there are clinical differences that might alter which one you choose. Comparing Ropinirole and Pramipexole Pharmacokinetics The most obvious difference when comparing ropinirole and pramipexole involves pharmacokinetic differences.
FDA Approval The FDA has recently approved two generic versions of apixaban and from the amount of apixaban I’m seeing used in clinical practice, this is a great thing for overall healthcare and drug costs. Here’s the FDA’s statement. Because of this switch to generic apixaban availability as well as the recent 2019 atrial fibrillation […].
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content